Ok so here is a summary of the answers i have received - all replies have been approved by management.
HCT – PHONE QUESTIONS
I have several questions regarding HCT and how the company is currently progressing
US
How are sales going in America ?
There have been many developments. HCT will provide a market update at the end of May.
Have you been able to secure enough bottles to fill this order ?
HCT have solved this. There is no more shipping from Asia. They have 3 bottling options that can do combined 150,000 bottles a week. Which can scale to suit demand.
My opinion – do the maths on this, and how many bottles at this stage can be produced a year, Massive.
When is the payment of $3.8m expected to by transferred to HCT ?
As above, half on order – half on completion.
How is HCT going with securing bottling plants to meet demand ?
As above
UK
Next i wanted to ask about the uk : the deal with OOH medical – have they put an order in yet and if so what size or if not when is this expected ?
An announcement regarding this will be released once numbers are finalised and UK registration has been determined.
With sole distribution rights do you feel they are the right company for the job ?
Yes, if you look up who is on the OOH board you will see why, good track record – well presented, established and connected
Do you plan to bottle in the UK or where is there distribution going to come from ?
HCT would prefer bottling to be done locally across all markets.
Europe
Is there any plans to appoint a sales director in Europe ?
Europe is a very big place – Best to segregate the distribution to several companies or give contracts to distributors that perform well. HCT will work with a network of distributors in different part of Europe.
If so is there currently someone in mind ?
HCT are currently in discussion with several groups
What size order are you expecting from them ?
HCT is awaiting European registration before an order confirmation can be released
Cash
How is the current cash situation looking for HCT ?
Sufficient for the near term including future plans
Personal note – i have said before that in the last ten years HCT has gone from 130m shares to 275m – management want to minimise dilution as much as possible
Do you feel a capital raising will be needed soon ?
As above
Is it likely you will secure a premium for this ?
There has been multiple parties who have expressed their interest in funding HCT should a cap raise be required – It is not just about taking the best cash offer – It is more about securing a company that is going to not only offer a premium but will also need to be very well connected to promote HCT’s products and a willingness to ESCROW their shares regarding this will be seen as a positive.
GENERAL
What developments are in store for HCT as a company over the next 6 months ?
- Secure an Aussie presence and Develop the business in North America and Europe
- Secure distributors in South America
- Launch the one in a kind nasal balm product
- Rollout the low GI range of products.
Can you comment on the top 20 holders in specific, 1. Have Aquity sold out ?
Acquity sold all their collateral shares on 20th April and do not hold any position in the company and their Controlled Placement Agreement with the company has ended.
Has management sold anylately ?
NO
Have there been any others sellingout ?
Major shareholders old and new have held their positions
whatpercentage does the top 20 currently hold ?
Around the 70% mark
What happened with Julia being hired as PR and terminated within the same week ?
Their month to month contract with us was not renewed.
Has she been replaced by an australian rep or is their plans ?
There has been multiple offers regarding this but currently in the vetting process
With SKN the australian partner likely in trouble with the ASX is their a backup plan to distribute to Aus/NZ ?
All we know is what is in the public domain and we cannot comment further.
QUESTIONS FROM FELLOW SHAREHOLDERS
1) when is a revised investor overview expected to be released to ASX ?
At this stage their is plans for a presentation around mid july
2) are there any plans for a South American launch of Natshield ?
There has been multiple expressions of interest from distributors – so yes, natshield is planning to go global.
3)What are the most likely other geographies currently not covered we can expect news on in near term?
HCT and its distributors are well connected throughout regions not currently covered and discussions with potential new countries are currently underway
4) what volume of nasel balm production is initally anticipated in US?
A business plan is being developed and will be communicated to the market as soon as this is firmed up
5) what is the strategy for low GI pasta global distribution and are any of the Natshield distributor relationships helping accelerate this ?
We have intentionally kept the business of low GI and Natshield separate
6) are there currently other companies in discussion with HCT regarding 80less sugar ?
Multiple companies are in discussion and are currently reformulating their products to qualify for the low sugar approval using this one of a kind formulation
7) are any active discussions occurring on Cannaboids regarding the absorption technology ?
HCT are in active discussions with several companies
8) what is the likely volume of pathaway that would be expected to be required if HK airport trial is successful ?
I liked the answer here, “we know it works, they know it works” no more to say on that
HCT is awaiting to get specific data from their trials to refine and optimise the delivery system
9) is there currently any plans to trial natshield in hospitals ?
No- no trials are currently in place
10)are other opportunities currently underway for Pathaway ? Particularly regarding the use in farming and animal management ?
Yes, a huge sector but they have not yet initiated something here
10) how is the TGA approval process currently tracking ?
HCT are now working with the TGA on this
11) it was mentioned there is additional testing being done in the US and UK, is this against the human strain ? And when are results expected on this ?
The Centers for Disease Control and Prevention (CDC) has categorised SARS-CoV-2 virus as biohazard level 3 and above. This means the virus will not currently be available for commercial testing at this point in the pandemic.
That is why HCT used the feline coronavirus which is the internationally accepted surrogate to SARS-CoV-2 virus . While this UK test allows HCT to conclude that “Natshield kills 99.99% of coronaviruses”, HCT are now proceeding to test versus the actual SARS-CoV-2 (COVID-19) at a CDC approved lab.